What happens if Rivaroxaban is discontinued prematurely?

Rivaroxaban is an oral anticoagulant that works by inhibiting Factor Xa in the coagulation cascade, thereby reducing the formation of blood clots. When Rivaroxaban is discontinued prematurely, there is a significant increase in the thrombotic risk. This occurs because the anticoagulation effect is lost, allowing the potential for clots to form, which can lead to serious complications such as stroke, venous thromboembolism, or other thrombotic events.

The risk of thrombosis is particularly concerning in patients who were originally treated with Rivaroxaban for conditions such as atrial fibrillation or after certain surgical procedures where there is a higher baseline risk for clot formation. Thus, ensuring consistent and appropriate anticoagulation therapy is critical to maintaining protective effects against thromboembolic events.

The other options do not accurately describe the consequences of prematurely discontinuing Rivaroxaban. Lowering blood pressure, activating the renin-angiotensin system, and causing kidney failure are not direct effects related to the abrupt cessation of this medication.